Abstract
Cardiovascular diseases are the most frequent cause of death in the world. Since ancient times, people used medicinal plants to cure a variety of ailments. Herbal treatment has not lost its relevance for today. The medicinal plant raw material used in scientific and folk medicine to improve the state of the cardiovascular system includes hawthorn fruits, mint leaves, lemon balm leaves and Greek valerian roots.Aim. To conduct the pharmacotechnological studies on the development of the composition and technology for the oral solid dosage form intended for prevention and treatment of cardiovascular diseases.Materials and methods. Powders of the plant raw material were studied by the following parameters: bulk density, flowability and moisture content. The microscopic analysis of powder particles was performed. The pharmacotechnological parameters of the model mixtures of active pharmaceutical ingredients with addition of excipients – flowability, compressibility and disintegration – were determined.Results and discussion. The microscopic analysis has shown that the mixture of the powdered plant raw material is a polydisperse system with particles that differ in shape. Based on this analysis it is possible to predict the unsatisfactory flowability of the mixture and, therefore, the necessity for the inclusion of excipients. To determine the composition of excipients in the preparation being developed the pharmacotechnological parameters of the model mixtures of the plant powders with the addition of microcrystalline cellulose, lactose (FlawLac and CapsuLac) and corn starch were studied. The amount of each component was determined experimentally. To provide flowability the method of wet granulation was chosen.Conclusions. The study of physicochemical and pharmacotechnological properties of powders of the medicinal plant raw material has shown poor flow characteristics. In order to improve the technological properties of the mixture such excipients as microcrystalline cellulose, FlawLac and CapsuLac lactose, aerosil and calcium stearate have been added. The use of the wet granulation method has been substantiated to increase the flowability of the mass. As a moisturizer 5 % starch paste has been chosen. The parameters of drying of wet granules have been studied, and the temperature (55 ± 5) °C has been set.
Highlights
The microscopic analysis has shown that the mixture of the powdered plant raw material is a polydisperse system with particles that differ in shape
To determine the composition of excipients in the preparation being developed the pharmaco-technological parameters of the model mixtures of the plant powders with the addition of microcrystalline cellulose, lactose (FlawLac and CapsuLac) and corn starch were studied
In order to improve the technological properties of the mixture such excipients as microcrystalline cellulose, FlawLac and CapsuLac lactose, aerosil and calcium stearate have been added
Summary
Захворювання серцево-судинної системи є найбільш частою причиною смерті у світі. Ще за сивої давнини люди використовували лікарські рослини для зцілення різноманітних нездужань. Що використовується науковою та народною медициною для поліпшення стану серцево-судинної системи, належать плоди глоду, листя м’яти, листя меліси та корені синюхи. Провести фармакотехнологічні дослідження з розробки складу та технології виробництва пероральної твердої лікарської форми для профілактики та лікування серцево-судинних захворювань. Мікроскопічний аналіз показав, що суміш порошків подрібненої рослинної сировини є полідисперсною системою з частинками, які відрізняються за формою, на підставі чого можна спрогнозувати незадовільну текучість досліджуваної суміші та, відповідно, необхідність введення допоміжних речовин. Для визначення складу допоміжних речовин у розроблюваному препараті досліджували фармакотехнологічні показники модельних сумішей рослинних порошків з додаванням мікрокристалічної целюлози, лактози (марок FlawLac та CapsuLac) та крохмалю кукурудзяного. Для забезпечення текучості обрано метод вологого гранулювання. Aim. To conduct the pharmaco-technological studies on the development of the composition and technology for the oral solid dosage form intended for prevention and treatment of cardiovascular diseases
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
